Cancilico, a Dresden-based AI diagnostics startup specializing in blood cancer, secured €2.5 million in Seed funding to further develop its MyeloAID software for analyzing bone marrow samples with AI, aiming to improve blood cancer diagnostics.
Dresden medtech Cancilico closes €2.5M round to advance AI in oncology
January 20, 2026